Literature DB >> 28100434

MNX1: a novel prostate cancer oncogene.

Manjulika Das.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28100434     DOI: 10.1016/S1470-2045(16)30553-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient.

Authors:  Christopher A Miller; Sonika Dahiya; Tiandao Li; Robert S Fulton; Matthew D Smyth; Gavin P Dunn; Joshua B Rubin; Elaine R Mardis
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02

2.  MNX1 reduces sensitivity to anoikis by activating TrkB in human glioma cells.

Authors:  Lai Jiang; Shaojun Chen; Donggang Zhao; Jun Yan; Jiemin Chen; Chunlin Yang; Gang Zheng
Journal:  Mol Med Rep       Date:  2018-07-27       Impact factor: 2.952

3.  MNX1-AS1 is a functional oncogene that induces EMT and activates the AKT/mTOR pathway and MNX1 in breast cancer.

Authors:  Yue Cheng; Yiqi Pan; Yiyuan Pan; Ouchen Wang
Journal:  Cancer Manag Res       Date:  2019-01-17       Impact factor: 3.989

4.  Motor Neuron and Pancreas Homeobox 1 (MNX1) Is Involved in Promoting Squamous Cervical Cancer Proliferation via Regulating Cyclin E.

Authors:  Li Xiao; Li Hong; Wenfei Zheng
Journal:  Med Sci Monit       Date:  2019-08-22

5.  An induced pluripotent stem cell t(7;12)(q36;p13) acute myeloid leukemia model shows high expression of MNX1 and a block in differentiation of the erythroid and megakaryocytic lineages.

Authors:  Tina Nilsson; Ahmed Waraky; Anders Östlund; Susann Li; Anna Staffas; Julia Asp; Linda Fogelstrand; Jonas Abrahamsson; Lars Palmqvist
Journal:  Int J Cancer       Date:  2022-06-03       Impact factor: 7.316

6.  Knockdown of spindle pole body component 25 homolog inhibits cell proliferation and cycle progression in prostate cancer.

Authors:  Feilun Cui; Jianpeng Hu; Yu Fan; Jian Tan; Huaming Tang
Journal:  Oncol Lett       Date:  2018-02-08       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.